美国等待肝移植患者接受全口服直接抗病毒药物治疗是具有成本效益的治疗策略
研究构建决策分析马尔可夫模型,模拟1000例平均年龄50岁的丙型肝炎病毒(HCV)合并肝细胞癌(HCC)或失代偿期肝硬化(DCC)等待肝移植患者,比较移植前与移植后全口服直接抗病毒药物(DAA)治疗的卫生经济学结局。HCC分析中移植前策略每例11.48质量调整生命年、终身成本365,948美元,移植后为10.39和283,696美元;DCC分析中移植前为9.27和304,800美元,移植后为8.7和283,789美元;增量成本效果比分别为74,255美元(HCC)和36,583美元(DCC),移植前治疗为最具成本效益策略。
要点
- HCC等待肝移植患者移植前DAA治疗每例11.48质量调整生命年、成本365,948美元,移植后为10.39和283,696美元。
- DCC等待肝移植患者移植前DAA治疗每例9.27质量调整生命年、成本304,800美元,移植后为8.7和283,789美元。
- 移植前治疗增量成本效果比为74,255美元(HCC)和36,583美元(DCC),为最具成本效益策略。
核心结论
- 对于等待肝移植的HCV合并HCC或DCC患者,移植前使用高效全口服DAA方案可获得最佳健康结局,且是最具成本效益的策略。
研究设计与样本
- 构建决策分析马尔可夫模型,模拟HCC患者和DCC等待肝移植患者的HCV自然疾病进展。
- 模型随访假设的1000例患者队列,平均年龄50岁,时间跨度30年,采用美国第三方付款人视角。
- 比较移植前与移植后全口服DAA治疗的卫生与经济结局,持续病毒学应答率来自ASTRAL-4、SOLAR-1和SOLAR-2,成本来自RedBook、Medicare收费表和已发表文献。
主要发现
- HCC分析中,移植前策略每例11.48质量调整生命年、终身成本365,948美元,移植后策略为10.39和283,696美元。
- DCC分析中,移植前策略每例9.27质量调整生命年、终身成本304,800美元,移植后策略为8.7和283,789美元。
- 移植前策略在HCC和DCC人群中均为最具成本效益,增量成本效果比分别为74,255美元和36,583美元。
- 敏感性和情景分析显示,结果对移植后患者效用值、治疗持续病毒学应答率、肝移植成本和基线终末期肝病模型评分(仅DCC分析)最敏感。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: All-oral direct acting antivirals (DAAs) have been shown to have high safety and efficacy in treating patients with hepatitis C virus (HCV) awaiting liver transplant (LT). However, there is limited empirical evidence comparing the health and economic outcomes associated with treating patients pre-LT versus post-LT. The objective of this study was to analyze the cost-effectiveness of pre-LT versus post-LT treatment with an all-oral DAA regimen among HCV patients with hepatocellular carcinoma (HCC) or decompensated cirrhosis (DCC). We constructed decision-analytic Markov models of the natural disease progression of HCV in HCC patients and DCC patients waitlisted for LT. The model followed hypothetical cohorts of 1,000 patients with a mean age of 50 over a 30-year time horizon from a third-party US payer perspective and estimated their health and cost outcomes based on pre-LT versus post-LT treatment with an all-oral DAA regimen. Transition probabilities and utilities were based on the literature and hepatologist consensus. Sustained virological response rates were sourced from ASTRAL-4, SOLAR-1, and SOLAR-2. Costs were sourced from RedBook, Medicare fee schedules, and published literature. In the HCC analysis, the pre-LT treatment strategy resulted in 11.48 per-patient quality-adjusted life years and $365,948 per patient lifetime costs versus 10.39 and $283,696, respectively, in the post-LT arm. In the DCC analysis, the pre-LT treatment strategy resulted in 9.27 per-patient quality-adjusted life years and $304,800 per patient lifetime costs versus 8.7 and $283,789, respectively, in the post-LT arm. As such, the pre-LT treatment strategy was found to be the most cost-effective in both populations with an incremental cost-effectiveness ratio of $74,255 (HCC) and $36,583 (DCC). Sensitivity and scenario analyses showed that results were most sensitive to the utility of patients post-LT, treatment sustained virological response rates, LT costs, and baseline Model for End-Stage Liver Disease score (DCC analysis only). CONCLUSION: The timing of initiation of antiviral treatment for HCV patients with HCC or DCC relative to LT is an important area of clinical and policy research; our results indicate that pre-LT treatment with a highly effective, all-oral DAA regimen provides the best health outcomes and is the most cost-effective strategy for the treatment of HCV patients with HCC or DCC waitlisted for LT. (Hepatology 2017;66:46-56).
引用
- Ahmed A, Gonzalez SA, Cholankeril G, et al. Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. Hepatology. 2017. PMID: 28257591. doi:10.1002/hep.29137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。